CXCR4 cell surface expression is critical for the homing of T regulatory (Treg) cells to the bone marrow (BM). We hypothesize that CXCR4 enrichment on Tregs cell surface may abbreviate their transit time to reach BM. Umbilical cord-blood CD25 Tregs underwent CXCR4 dual enrichment and expansion using the CRANE process to generate CXCR4-enriched Tregs (Treg) cells, which showed a faster migration across the Transwell membrane toward CXCL12/stromal cell-derived factor 1α (SDF1α) at 15, 30, and 60 min, when compared to unmanipulated Treg cells ( < 0.0001). Treg exhibited preferential homing to BM at 12 and 24 h. Metacluster analysis of BM showed a decrease in CD8 and an increase in CD39 and CD73 and CXCR5 when compared to Treg. Treg decreased plasma TGF-β1/β2 and IFN-γ levels. When compared to control, Treg cells decreased in CD8 T cell, IFN-γ, and TNF-α expression in BM. We conclude that Treg show enhanced migration toward CXCL12/SDF1α and a preferential homing to BM resulting in resolution of inflammation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418154PMC
http://dx.doi.org/10.1016/j.isci.2024.110830DOI Listing

Publication Analysis

Top Keywords

treg cells
12
bone marrow
8
cell surface
8
cxcr4-enriched regulatory
4
cells
4
regulatory cells
4
cells preferentially
4
preferentially bone
4
marrow resolve
4
resolve inflammation
4

Similar Publications

Estrogen sulfotransferase (SULT1E1), a member of the sulfotransferase family (SULTs), is the enzyme with the strongest affinity for estrogen. Despite significant associations between SULT1E1 and the progression and prognosis of a range of diseases, its functional role and potential mechanisms in lung adenocarcinoma (LUAD) remain unclear. The objective of this study was to examine the potential of SULT1E1 as a biomarker for LUAD.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8 T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment.

View Article and Find Full Text PDF

Potential regulation of artesunate on bone metabolism through suppressing inflammatory infiltration in type 2 diabetes mellitus.

Immunopharmacol Immunotoxicol

January 2025

Department of Oral & Maxillofacial Surgery, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, China.

Objective: Osteoimmunology is an emerging field that explores the interplay between bone and the immune system. The immune system plays a critical role in the pathogenesis of diabetes and significantly affects bone homeostasis. Artesunate, a first-line treatment for malaria, is known for its low toxicity and multifunctional properties.

View Article and Find Full Text PDF

FoxP3 T-regulatory (Treg) lymphocytes and cytokine production by cells from the stromal vascular fraction (SVF) of epicardial (EAT) and thymus (TAT) adipose tissue of 42 patients with chronic coronary heart disease (CHD) were studied. In the SVF of TAT in patients with Gensini Score (GS)≥74 (the most severe atherosclerosis), the production of IL-1β, TNF, IL-4, and IFNγ was higher, while FoxP3 translocation into the nucleus was lower than in patients with GS<74. The GS index directly correlated with the production of IL-4, IL-1β, and TNF by cells of the SVF of TAT, and inversely - with the production of TNF, IL-17, and IL-10 by cells of the SVF of EAT.

View Article and Find Full Text PDF

Dose effect of corticosteroids on peripheral lymphocyte profiles in patients with systemic lupus erythematosus.

Clin Rheumatol

January 2025

Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.

Objective: To investigate the dose effect of methylprednisolone (MP) on peripheral lymphocyte profiles in patients with systemic lupus erythematosus (SLE). This study investigated the impact of varied MP doses on peripheral lymphocyte subtypes in SLE patients.

Methods: We conducted a prospective study involving 51 SLE patients, categorized into four groups (40 mg/day, 80 mg/day, 500 mg/day, and 1000 mg/day) based on the administered MP dosage during hospitalization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!